Brief: Shilpa Medicare Says Shilpa Biologics Gets Market Approval For Adalimumab 40 Mg/0.4 Ml Solution For Injection In Morocco
23/07/2024 07:42
July 23 (Reuters) - Shilpa Medicare Ltd SHME.NS :
* GOT MARKET APPROVAL FOR ADALIMUMAB 40 MG/0.4 ML SOLUTION
FOR
INJECTION IN MOROCCO
Source text for Eikon: ID:nBSE2hykn
Further company coverage: SHME.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026